Last reviewed · How we verify
GnRHa: leuprolide
At a glance
| Generic name | GnRHa: leuprolide |
|---|---|
| Also known as | Lupron |
| Sponsor | University of Sao Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
- RWE About QOL and Compliance of Patients With OFS in China
- GnRH-a on Angiogenesis of Endometriosis (NA)
- Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (PHASE2, PHASE3)
- A Multicenter Open-label Clinical Study on the Prevention of Premature Ovarian Failure After HSCT (NA)
- A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
- Psychological Impact of Amenorrhea in Women With Endometriosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GnRHa: leuprolide CI brief — competitive landscape report
- GnRHa: leuprolide updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI